EP3525784
SPARSENTAN FOR USE IN THE TREATMENT OF ALPORT SYNDROME
Status:
EP einkaleyfi: EP einkaleyfi tilnefnt til gildistöku á ÍslandiEP appl. date:
13.10.2017EP published:
28.1.2026EP application number:
17791821.6
EPO information:
European Patent Register
Max expiry date:
12.10.2037Expiry date:
12.10.2026
Title in English:
SPARSENTAN FOR USE IN THE TREATMENT OF ALPORT SYNDROMELanguage of the patent:
English
Timeline
Today
13.10.2017EP application
28.1.2026EP Publication
12.10.2026Expires
Owner
Name:
Travere Therapeutics, Inc.Address:
3611 Valley Centre Drive Suite 300, San Diego CA 92130, US
Inventor
Name:
KOMERS, RadkoAddress:
Portland, Oregon 97219, US
Name:
SHIH, AlvinAddress:
Newton, Massachusetts 02468, US
Priority
Number:
201662407860 PDate:
13.10.2016Country:
US
Number:
201662423079 PDate:
16.11.2016Country:
US
Classification
Categories:
A61K 31/422, A61P 13/12, A61P 43/00